Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Perfluorocarbon Labeling of Human Glial-Restricted Progenitors for 19 F Magnetic Resonance Imaging.

Richard JP, Hussain U, Gross S, Taga A, Kouser M, Almad A, Campanelli JT, Bulte JWM, Maragakis NJ.

Stem Cells Transl Med. 2019 Apr;8(4):355-365. doi: 10.1002/sctm.18-0094. Epub 2019 Jan 7.

2.

Current and emerging ALS biomarkers: utility and potential in clinical trials.

Taga A, Maragakis NJ.

Expert Rev Neurother. 2018 Nov;18(11):871-886. doi: 10.1080/14737175.2018.1530987. Epub 2018 Oct 8.

PMID:
30273061
3.

Olfactory dysfunction in amyotrophic lateral sclerosis.

Viguera C, Wang J, Mosmiller E, Cerezo A, Maragakis NJ.

Ann Clin Transl Neurol. 2018 Jun 19;5(8):976-981. doi: 10.1002/acn3.594. eCollection 2018 Aug.

4.

Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis.

Hoye ML, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S, Richard JP, Maragakis NJ, Rothstein JD, Dougherty JD, Miller TM.

Brain. 2018 Sep 1;141(9):2561-2575. doi: 10.1093/brain/awy182.

PMID:
30007309
5.

A stocked toolbox for understanding the role of astrocytes in disease.

Almad A, Maragakis NJ.

Nat Rev Neurol. 2018 Jun;14(6):351-362. doi: 10.1038/s41582-018-0010-2. Review.

PMID:
29769699
6.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

7.

A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis.

Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley KM, Yu H, Schoenfeld DA, Maragakis NJ; neals consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):250-258. doi: 10.1080/21678421.2017.1404108. Epub 2017 Nov 30.

PMID:
29191052
8.

Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients.

Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, Ravits JM, Miller TM, Maragakis NJ, Hales CM, Glass JD, Gross S, Mitsumoto H, Manfredi G.

Mol Neurodegener. 2017 Oct 24;12(1):76. doi: 10.1186/s13024-017-0217-5.

9.

Erratum.

Beart P, Robinson M, Rattray M, Maragakis NJ.

Adv Neurobiol. 2017;15:E1. doi: 10.1007/978-3-319-57193-5_21. No abstract available.

PMID:
28905310
10.

What can we learn from the edaravone development program for ALS?

Maragakis NJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):98-103. doi: 10.1080/21678421.2017.1361446. Review.

PMID:
28872911
11.

Motoneuron Disease: Clinical.

Ilieva H, Maragakis NJ.

Adv Neurobiol. 2017;15:191-210. doi: 10.1007/978-3-319-57193-5_7. Review.

PMID:
28674982
12.

Motoneuron Disease: Basic Science.

Ilieva H, Maragakis NJ.

Adv Neurobiol. 2017;15:163-190. doi: 10.1007/978-3-319-57193-5_6. Review.

PMID:
28674981
13.

MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.

Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O'Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, Dougherty JD, Miller TM.

J Neurosci. 2017 May 31;37(22):5574-5586. doi: 10.1523/JNEUROSCI.3582-16.2017. Epub 2017 Apr 17.

14.

Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo.

Qian K, Huang H, Peterson A, Hu B, Maragakis NJ, Ming GL, Chen H, Zhang SC.

Stem Cell Reports. 2017 Apr 11;8(4):843-855. doi: 10.1016/j.stemcr.2017.03.003. Epub 2017 Mar 30.

15.

Serial in vivo imaging of transplanted allogeneic neural stem cell survival in a mouse model of amyotrophic lateral sclerosis.

Srivastava AK, Gross SK, Almad AA, Bulte CA, Maragakis NJ, Bulte JWM.

Exp Neurol. 2017 Mar;289:96-102. doi: 10.1016/j.expneurol.2016.12.011. Epub 2016 Dec 28.

16.

Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.

17.

Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.

Qosa H, Lichter J, Sarlo M, Markandaiah SS, McAvoy K, Richard JP, Jablonski MR, Maragakis NJ, Pasinelli P, Trotti D.

Glia. 2016 Aug;64(8):1298-313. doi: 10.1002/glia.23003. Epub 2016 May 9.

18.

Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis.

Almad AA, Doreswamy A, Gross SK, Richard JP, Huo Y, Haughey N, Maragakis NJ.

Glia. 2016 Jul;64(7):1154-69. doi: 10.1002/glia.22989. Epub 2016 Apr 16.

19.

Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N.

J Clin Neuromuscul Dis. 2016 Mar;17(3):99-105. doi: 10.1097/CND.0000000000000102.

20.

Hemiparetic Primary Lateral Sclerosis: Revisiting Mills Syndrome.

Maragakis NJ, Holland NR, Corse AM.

Case Rep Neurol. 2013 Sep 24;7(3):191-5. doi: 10.1159/000440713. eCollection 2015 Sep-Dec.

21.

Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology.

Zhang PW, Haidet-Phillips AM, Pham JT, Lee Y, Huo Y, Tienari PJ, Maragakis NJ, Sattler R, Rothstein JD.

Glia. 2016 Jan;64(1):63-75. doi: 10.1002/glia.22903. Epub 2015 Aug 21.

22.

Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury.

Li K, Javed E, Scura D, Hala TJ, Seetharam S, Falnikar A, Richard JP, Chorath A, Maragakis NJ, Wright MC, Lepore AC.

Exp Neurol. 2015 Sep;271:479-92. doi: 10.1016/j.expneurol.2015.07.020. Epub 2015 Jul 26.

23.

Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS).

Haidet-Phillips AM, Maragakis NJ.

Brain Res. 2015 Dec 2;1628(Pt B):343-350. doi: 10.1016/j.brainres.2015.06.035. Epub 2015 Jul 14. Review.

PMID:
26187754
24.

A comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cells.

Li Y, Balasubramanian U, Cohen D, Zhang PW, Mosmiller E, Sattler R, Maragakis NJ, Rothstein JD.

PLoS One. 2015 Mar 11;10(3):e0118266. doi: 10.1371/journal.pone.0118266. eCollection 2015.

25.

Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency.

Grunseich C, Schindler AB, Chen KL, Bakar D, Mankodi A, Traslavina R, Ray-Chaudhury A, Lehky TJ, Baker EH, Maragakis NJ, Tifft CJ, Fischbeck KH.

J Neurol. 2015;262(4):1066-8. doi: 10.1007/s00415-015-7683-x. Epub 2015 Mar 4. No abstract available.

26.

Human glial progenitor engraftment and gene expression is independent of the ALS environment.

Haidet-Phillips AM, Doreswamy A, Gross SK, Tang X, Campanelli JT, Maragakis NJ.

Exp Neurol. 2015 Feb;264:188-99. doi: 10.1016/j.expneurol.2014.12.011. Epub 2014 Dec 16.

27.

Transplantation of glial progenitors that overexpress glutamate transporter GLT1 preserves diaphragm function following cervical SCI.

Li K, Javed E, Hala TJ, Sannie D, Regan KA, Maragakis NJ, Wright MC, Poulsen DJ, Lepore AC.

Mol Ther. 2015 Mar;23(3):533-48. doi: 10.1038/mt.2014.236. Epub 2014 Dec 10.

28.

Induced pluripotent stem cells from ALS patients for disease modeling.

Richard JP, Maragakis NJ.

Brain Res. 2015 May 14;1607:15-25. doi: 10.1016/j.brainres.2014.09.017. Epub 2014 Sep 16. Review.

29.

Gene profiling of human induced pluripotent stem cell-derived astrocyte progenitors following spinal cord engraftment.

Haidet-Phillips AM, Roybon L, Gross SK, Tuteja A, Donnelly CJ, Richard JP, Ko M, Sherman A, Eggan K, Henderson CE, Maragakis NJ.

Stem Cells Transl Med. 2014 May;3(5):575-85. doi: 10.5966/sctm.2013-0153. Epub 2014 Mar 6.

30.

C9orf72 nucleotide repeat structures initiate molecular cascades of disease.

Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, Rothstein JD, Wang J.

Nature. 2014 Mar 13;507(7491):195-200. doi: 10.1038/nature13124. Epub 2014 Mar 5.

31.

Electrical impedance myography correlates with standard measures of ALS severity.

Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Benatar M, Sharma KR, Narayanaswami P, Raynor EM, Watson ML, Shefner JM.

Muscle Nerve. 2014 Mar;49(3):441-3. doi: 10.1002/mus.24128. Epub 2013 Dec 19.

PMID:
24273034
32.

Altered astrocytic expression of TDP-43 does not influence motor neuron survival.

Haidet-Phillips AM, Gross SK, Williams T, Tuteja A, Sherman A, Ko M, Jeong YH, Wong PC, Maragakis NJ.

Exp Neurol. 2013 Dec;250:250-9. doi: 10.1016/j.expneurol.2013.10.004. Epub 2013 Oct 9.

PMID:
24120466
33.

Exome sequencing to identify de novo mutations in sporadic ALS trios.

Chesi A, Staahl BT, Jovičić A, Couthouis J, Fasolino M, Raphael AR, Yamazaki T, Elias L, Polak M, Kelly C, Williams KL, Fifita JA, Maragakis NJ, Nicholson GA, King OD, Reed R, Crabtree GR, Blair IP, Glass JD, Gitler AD.

Nat Neurosci. 2013 Jul;16(7):851-5. doi: 10.1038/nn.3412. Epub 2013 May 26.

34.

Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis.

Roth NM, Saidha S, Zimmermann H, Brandt AU, Oberwahrenbrock T, Maragakis NJ, Tumani H, Ludolph AC, Meyer T, Calabresi PA, Paul F.

Eur J Neurol. 2013 Aug;20(8):1170-6. doi: 10.1111/ene.12146. Epub 2013 Apr 14.

PMID:
23582075
35.

Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis.

Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, Lachyankar MB, Marconi M, Li J, Yu D, Han I, Maragakis NJ, Lládo J, Erkmen K, Redmond DE Jr, Sidman RL, Przedborski S, Rothstein JD, Brown RH Jr, Snyder EY.

Sci Transl Med. 2012 Dec 19;4(165):165ra164. doi: 10.1126/scitranslmed.3004579.

PMID:
23253611
36.

Glia: an emerging target for neurological disease therapy.

Almad AA, Maragakis NJ.

Stem Cell Res Ther. 2012 Sep 28;3(5):37. doi: 10.1186/scrt128. Review.

37.

Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.

Wray S, Self M; NINDS Parkinson's Disease iPSC Consortium; NINDS Huntington's Disease iPSC Consortium; NINDS ALS iPSC Consortium, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, Marti-Masso JF, Preza E, Barker S, Sutherland M, Corriveau RA, D'Andrea M, Schapira AH, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Espay AJ, Slawek J, Gutmann L, Boeve BF, Boylan K, Stoessl AJ, Ross OA, Maragakis NJ, Van Gerpen J, Gerstenhaber M, Gwinn K, Dawson TM, Isacson O, Marder KS, Clark LN, Przedborski SE, Finkbeiner S, Rothstein JD, Wszolek ZK, Rossor MN, Hardy J.

PLoS One. 2012;7(8):e43099. doi: 10.1371/journal.pone.0043099. Epub 2012 Aug 27.

38.

Selected statins produce rapid spinal motor neuron loss in vitro.

Murinson BB, Haughey NJ, Maragakis NJ.

BMC Musculoskelet Disord. 2012 Jun 15;13:100. doi: 10.1186/1471-2474-13-100.

39.

Electrical impedance myography as a biomarker to assess ALS progression.

Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Clawson L, Benatar M, Usher S, Sharma KR, Gautam S, Narayanaswami P, Raynor EM, Watson ML, Shefner JM.

Amyotroph Lateral Scler. 2012 Sep;13(5):439-45. doi: 10.3109/17482968.2012.688837. Epub 2012 Jun 7.

40.

Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.

Jablonski MR, Jacob DA, Campos C, Miller DS, Maragakis NJ, Pasinelli P, Trotti D.

Neurobiol Dis. 2012 Aug;47(2):194-200. doi: 10.1016/j.nbd.2012.03.040. Epub 2012 Apr 11.

41.

Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS.

Lepore AC, O'Donnell J, Kim AS, Williams T, Tuteja A, Rao MS, Kelley LL, Campanelli JT, Maragakis NJ.

PLoS One. 2011;6(10):e25968. doi: 10.1371/journal.pone.0025968. Epub 2011 Oct 5.

42.

Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo.

Papadeas ST, Kraig SE, O'Banion C, Lepore AC, Maragakis NJ.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17803-8. doi: 10.1073/pnas.1103141108. Epub 2011 Oct 3.

43.

Stem cell transplantation for spinal cord neurodegeneration.

Lepore AC, Maragakis NJ.

Methods Mol Biol. 2011;793:479-93. doi: 10.1007/978-1-61779-328-8_31.

PMID:
21913120
44.

Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury.

Lepore AC, O'Donnell J, Kim AS, Yang EJ, Tuteja A, Haidet-Phillips A, O'Banion CP, Maragakis NJ.

Glia. 2011 Dec;59(12):1996-2005. doi: 10.1002/glia.21241. Epub 2011 Aug 31.

45.

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, Benatar M, David WS, Sharma KR, Rutkove SB.

Neurology. 2011 Jul 19;77(3):235-41. doi: 10.1212/WNL.0b013e318225aabf. Epub 2011 Jun 15.

46.

Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury.

Lepore AC, O'Donnell J, Bonner JF, Paul C, Miller ME, Rauck B, Kushner RA, Rothstein JD, Fischer I, Maragakis NJ.

J Neurosci Res. 2011 Jul;89(7):1001-17. doi: 10.1002/jnr.22624. Epub 2011 Apr 12.

PMID:
21488085
47.

Stem cells and the ALS neurologist.

Maragakis NJ.

Amyotroph Lateral Scler. 2010 Oct;11(5):417-23. doi: 10.3109/17482968.2010.489116. Review.

PMID:
20509745
48.

Peripheral hyperstimulation alters site of disease onset and course in SOD1 rats.

Lepore AC, Tolmie C, O'Donnell J, Wright MC, Dejea C, Rauck B, Hoke A, Ignagni AR, Onders RP, Maragakis NJ.

Neurobiol Dis. 2010 Sep;39(3):252-64. doi: 10.1016/j.nbd.2010.03.021. Epub 2010 Apr 8.

49.

Motor neuron disease: progressive muscular atrophy in the ALS spectrum.

Maragakis NJ.

Nat Rev Neurol. 2010 Apr;6(4):187-8. doi: 10.1038/nrneurol.2010.29. No abstract available.

PMID:
20379201
50.

Advances in stem cell research for Amyotrophic Lateral Sclerosis.

Papadeas ST, Maragakis NJ.

Curr Opin Biotechnol. 2009 Oct;20(5):545-51. doi: 10.1016/j.copbio.2009.09.003. Epub 2009 Oct 12. Review.

PMID:
19819686

Supplemental Content

Loading ...
Support Center